EBV BRLF1 (148-156) (HLA-A3) – Immunology – Antigens/Epitotes/Pools/Librairies

EBV BRLF1 (148-156) (HLA-A3) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV). EBV targets B cells, which can cause lytic infection and the consequent death of these cells. Natural killer (NK) cells, invariant (iNKT) cells, CD4T cells and CD8 T cells are essential to control the action of EBV-infected cells. EBV BRLF1 (148-156) (HLA-A3) is defined as a CEF control peptide due to its antigenic properties. Clinically, this peptide is a suitable epitope for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-A3 refers to the cell HLA type that this peptide acts on. The BRLF1 protein is a transcriptional activator that interacts with the amino and carboxy termini of the CREB-binding protein (CBP). CBP activates the lytic EBV gene SM, meaning the interaction between CBP and BRLF1 is responsible for EBV particles switching from latent to lytic viral replication.